Breaking News
October 22, 2018 - Overcoming bottlenecks in early drug discovery with the power of sound
October 22, 2018 - Scientists discover genes that contribute to ADHD development
October 22, 2018 - Incyte announces Phase 2 FIGHT-202 trial data in patients with cholangiocarcinoma
October 22, 2018 - FDA approves update to Rituxan label to include information on treatment of rare forms of vasculitis
October 22, 2018 - At-home biofeedback therapy effective in relieving difficult-to-treat constipation
October 22, 2018 - Merck presents KEYNOTE-057 trial results for patients with high-risk non-muscle invasive bladder cancer
October 22, 2018 - People with periodontal disease less likely to reach healthy blood pressure ranges
October 22, 2018 - Phase III LONSURF study shows progression-free survival in patients with refractory metastatic gastric cancer
October 22, 2018 - Primary care doctors ‘not doing enough’ to curb STDs
October 22, 2018 - Pfizer announces PALOMA-3 trial results in patients with HR+, HER2- metastatic breast cancer
October 22, 2018 - ImmunoGen announces study results of platinum-resistant ovarian cancer therapy at ESMO 2018 Congress
October 22, 2018 - Study findings could set new standard of care for advanced anal cancer
October 22, 2018 - Erlotinib improves progression-free survival in EGFR mutated NSCLC
October 22, 2018 - Pain, insomnia, and depression often drive osteoarthritis patients to seek medical care
October 22, 2018 - The International Society of Refractive Surgery honors Vivior Chairman with Casebeer Award
October 22, 2018 - Multi-strain probiotic helps reduce chemotherapy-induced diarrhea in cancer patients
October 22, 2018 - Study shows potential of avelumab plus axitinib as new treatment option for patients with advanced RCC
October 22, 2018 - Vertex gets European CHMP positive opinion for KALYDECO to treat patients with cystic fibrosis
October 22, 2018 - Phase III trial reports positive results with HDAC inhibitor in advanced breast cancer patients
October 22, 2018 - Prostate radiotherapy improves survival in men with low burden of metastatic disease
October 22, 2018 - Free phone app helps low-income obese patients to lose weight
October 22, 2018 - Immunotherapy with nivolumab and ipilimumab may improve survival in patients with MSI-high metastatic colorectal cancers
October 22, 2018 - FOTIVDA expected to be included in new ESMO guidelines for advanced renal cell carcinoma
October 22, 2018 - Compression Collar May Protect Brain of Female Soccer Players
October 22, 2018 - Technique visualizes neuron communication
October 22, 2018 - Advancement in medical imaging methods for health care
October 22, 2018 - Takeda presents vedolizumab phase 3 VISIBLE 1 trial results for treatment of moderately to severely active ulcerative colitis
October 22, 2018 - Immunotherapy increases survival in some patients with metastatic triple negative breast cancer
October 22, 2018 - Exelixis presents CABOSUN and METEOR trial results in patients with advanced renal cell carcinoma
October 22, 2018 - LYNPARZA Phase III SOLO-1 results show improved outcome for patients with advanced BRCA-mutated ovarian cancer
October 22, 2018 - Brainlab unveils ExacTrac Dynamic at ASTRO meeting in San Antonio, Texas
October 22, 2018 - Not exercising is worse than smoking, diabetes or heart disease finds study
October 22, 2018 - Shorter course of trastuzumab could be an option for women with HER2+ early breast cancer
October 22, 2018 - Map of Mouse Hippocampus Could Be Weapon Against Alzheimer’s
October 22, 2018 - Psychotropic polypharmacy is common in Alzheimer’s disease
October 22, 2018 - Texas A&M and UTA establish Texas Genomics Core Alliance
October 22, 2018 - Analyzing mouse’s potential as animal model of decision-making
October 22, 2018 - Radiotherapy can prolong survival in prostate cancer
October 22, 2018 - A genetic mutation involved in relapse
October 21, 2018 - Report reveals growing impact of cannabis on young people
October 21, 2018 - NSF awards $5 million grant to help scientists magnify societal impact of research
October 21, 2018 - Fertility Rates Down for Each Urbanization Level 2007 to 2017
October 21, 2018 - Genetically engineered 3-D human muscle transplant in a murine model
October 21, 2018 - Moms’ tight work schedules may affect their children’s sleep
October 21, 2018 - AHA: No Direct Link Between Preeclampsia and Cognitive Impairment, Study Finds
October 21, 2018 - Weight loss success linked with active self-control regions of the brain
October 21, 2018 - Scripps researchers successfully test potential new smoking-cessation treatment in rodents
October 21, 2018 - More accurate and less stressful way to measure a baby’s heartbeat
October 21, 2018 - Researchers show better cardiorespiratory fitness leads to longer life
October 21, 2018 - Healthy candies for diabetic patients
October 21, 2018 - Environment impact of microplastics remains unclear
October 21, 2018 - Antibiotics for appendicitis? Surgery often not needed
October 21, 2018 - AHA and AMA recognize more than 800 medical practices, health systems for blood pressure control
October 21, 2018 - Scientists obtain clearest ever image of Ebola virus protein
October 21, 2018 - Study reveals connection between two proteins known to be hyperactive in cancer
October 21, 2018 - Gabapentin Beats Pregabalin for Chronic Sciatica
October 21, 2018 - Cosmetic surgeons offering incomplete information for breast augmentation customers
October 21, 2018 - Chronic sleep disruption in early adult life accelerates AD-related tau pathology
October 21, 2018 - Take 10 for Mindfulness – Drugs.com MedNews
October 21, 2018 - Length of breathing disruption in OSA may be better predictor of mortality risk
October 21, 2018 - ApoE4 gene linked with chronic inflammation increases risk for Alzheimer’s disease
October 21, 2018 - Mother-daughter conflict associated with suicide risk in abused adolescent girls
October 21, 2018 - Scientists molding bacteria into unnatural shapes
October 21, 2018 - High diet quality associated with lower risk of death in colorectal cancer patients
October 21, 2018 - Discharged mental health patients ‘at greater risk of dying’
October 21, 2018 - Research provides insight into neurobiology of aggression and bullying
October 21, 2018 - As billions in tax dollars flow to private Medicaid plans, Who’s minding the store?
October 21, 2018 - Neuroscientists identify brain region that appears to be related to food preference decisions
October 21, 2018 - Deaths related to air pollution in the U.S. decreased by 47% between 1990 and 2010
October 21, 2018 - Study shows correlation between spatial memory and the sense of smell
October 21, 2018 - Increased cardiorespiratory fitness associated with reduced long-term mortality
October 21, 2018 - IU researchers receive $1.55 million from NIH to improve chronic-disease management
October 21, 2018 - Income and wealth affect the mental health of Australians, study shows
October 21, 2018 - Patients with hypertension and psoriasis more often require cardiovascular interventions
October 20, 2018 - Leading hip-hop videos depict use of tobacco and marijuana products, study finds
October 20, 2018 - Dose Range of IV Ketamine for Adjunct Tx of Depression Tested
October 20, 2018 - Infants can distinguish between leaders and bullies, study finds
October 20, 2018 - Mad Cow disease found on Aberdeenshire farm
October 20, 2018 - Study identifies factors associated with prescription opioid misuse among students
October 20, 2018 - Scientists uncover key regulator of mTORC1 in cancer growth
Problems Continue To Plague Tumor Biomarker Tests

Problems Continue To Plague Tumor Biomarker Tests

image_pdfDownload PDFimage_print

Action Points

  • Not all tumor biomarker assays regarded as high-quality are highly congruent or have clinical relevance, according to results from two separate comparison studies.
  • Note that while laboratory-developed tests (LDTs) and FDA-approved companion diagnostics (FDA-CDs) both demonstrated a high degree of accuracy and excellent performance using uniform reference materials, results of analyses on non-standard materials show significant variability.

Not all high-quality tumor biomarker assays are highly congruent or have clinical relevance, results from two separate comparison studies showed.

In the first, laboratory-developed tests (LDTs) and FDA-approved companion diagnostics (FDA-CDs) both demonstrated a high degree of accuracy and excellent performance overall for three oncology analytes in College of American Pathologists (CAP) proficiency testing (PT), researchers said.

Pathological evaluation of tumors comparing LDTs and FDA-CDs in 6,897 proficiency responses showed that both test types exceeded 97% accuracy across all comparable molecular oncology proficiency testing samples for BRAF, EGFR, and KRAS genes, according to Annette S. Kim, MD, PhD, of Brigham and Women’s Hospital in Boston, and colleagues.

“These findings support both the excellent and equivalent performance of both LDTs and FDA-CDs in clinical diagnostic testing,” the study authors wrote in JAMA Oncology.

However, a comparison of laboratories’ pre-analytic practices showed more than 60% were using FDA-CDs outside the bounds of FDA-approved methods. Although participants said they made modifications to the FDA-CDs to increase the flexibility of clinical practice, this effectively rendered the assays LDTs, the study authors noted.

“Both FDA-CD and LDT laboratories accept a wide range of specimen preparations, as well as tumor types,” Kim and colleagues said. “Although this flexibility is advantageous for patient care, it is important to recognize that the use of specimens other than formalin-fixed paraffin-embedded samples of the specified tumor type for the FDA-CDs is off-label, resulting in reclassification of the assay as an LDT.”

Laboratories used the assay off-label by accepting specimens with lower tumor content than required for the approved FDA-CD assay, the study revealed. Other practice modifications included accepting unapproved specimen and tumor types, and not quantifying DNA before performing the FDA-CD assay.

In the study, PT responses were included for 2,524 BRAF (14 PT samples), 2,216 EGFR (11 PT samples), and 2,157 KRAS (10 PT samples). Approximately 15% of these assays were performed using commercially available FDA-CD kits and 85% were analyzed as LDTs.

There were no significant differences between LDTs and the FDA-CD acceptability rates for KRAS. The FDA-CDs performed less well than the LDTs for BRAF p.V600K analysis (CD 66.1% versus LDT 88.0%), and the LDT assay was inferior for EGFR p.L861Q mutation (CD 100% versus LDT 91%).

Noting the comparable performance of the two assays, the greater clinical relevance of LDTs and the “significant off-label use of FDA-CDs,” it might make more sense to reclassify FDA-CDs as LTDs, the researchers suggested.

In an accompanying editorial, Daniel F. Hayes, MD, of the University of Michigan Comprehensive Cancer Center, Ann Arbor, noted that a tumor biomarker test that has analytical validity but lacks clinical utility can’t be introduced into routine practice. “Therefore, approval of a tumor biomarker test by the FDA does not necessarily imply that it should be ordered or used to direct patient care,” he said.

In the era of precision oncology medicine, clinicians need to be knowledgeable about tumor biomarkers as well as the tests used to measure them, he added.

Although Hayes called the CAP proficiency testing “terrific” and said it “should make all of us who are clinicians sleep better at night,” he also pointed out that the study included only pathologists participating in the CAP proficiency testing.

“You should hope that your patient’s sample was tested in one of these laboratories and not in one that did not include these proficient pathologists,” he commented.

The number of tested specimens was low, Hayes said, who also zeroed in on the fact that more than half of the laboratories using FDA-CDs didn’t follow manufacturer’s instructions.

“Although it is reassuring that different laboratories using different techniques and assays usually came up with the same results for BRAF, EGFR, and KRAS, these results cannot be extrapolated to other, more complex tumor tests,” he concluded.

Wide Inter-Test Variability

In a related research letter in the same issue, Gonzalo Torga, MD, and Kenneth J. Pienta, MD, of Johns Hopkins University School of Medicine in Baltimore, reported findings from a small study showing very low patient-paired sample congruence between two liquid commercial biopsy tests. Both genetic tests had self-reported high accuracy, specificity, and sensitivity to detect and quantify tumor-specific alteration, and both laboratories were CAP-accredited for cfDNA next-generation sequencing.

However, in 40 patients with metastatic prostate cancer, 6 blood samples were unevaluable. In the remaining 34 samples, complete concordance between the two assays was observed in 9 (35%). The assays were partially concordant in six samples of the remaining 25, but in the last 16 samples, there was no concordance between the assays at all.

“These data cannot determine which test is more accurate but suggest that reported gene alterations will not be the same across different platforms, raising the specter that patients could potentially receive different treatments depending on the cfDNA platform,” the study authors said.

These results are “disturbing,” said Hayes, and have obvious implications for every clinician ordering laboratory-developed tests. Although LTDs have made important contributions to patient care, a lot of uncertainty remains about their accuracy and basis for use, Hayes added.

“I have often said that ‘a bad tumor biomarker test is as bad as a bad drug.’ Caveat emptor is not a good way to practice medicine, and I for one will continue to call for collegial and constructive measures to improve, and in many cases further regulate, tests that are so important for our patients.”

Lead study author Kim reported a relationship with Aushon Biosciences and a number of study co-authors also reported relationships with industry. Second study authors Torga and Pienta disclosed no potential conflicts of interest. Editorialist Hayes reported relationships with OncImmune, Inbiomotion, Merrimack Pharmaceuticals, Eli Lilly Company, Janssen, Menarini/Silicon bioSystems, Puma Biotechnology, Pfizer, AstraZeneca, and Menarini/Silicon bioSystems.

2017-12-19T13:30:00-0500

Tagged with:

About author

Related Articles